Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
United Kingdom Research and Innovation is managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners across 4 distinct art units. MOAZZAMI, NAGHMEH NINA is the busiest examiner, currently responsible for 1 pending office action. The portfolio shows a broad distribution of work, with different examiners each handling a portion of the actions.
The presence of 6 pending office actions across 4 distinct art units indicates that the company's research in Biotechnology & Pharmaceuticals is technically diverse. Since there are 6 distinct examiners involved, each of the pending office actions is being handled by a different person. MOAZZAMI, NAGHMEH NINA is identified as the busiest examiner even though they only have 1 pending office action. This reflects a highly fragmented prosecution landscape where no single examiner has a majority of the cases. Managing these actions requires coordination across 4 different art units, suggesting that the underlying technologies may involve various biological or pharmaceutical disciplines.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| KIEFER, DALTON EDWARD | 1 | 83.3% | +0.0% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547085 | FUSION PROTEINS COMPRISING TWO RING DOMAINS | KIEFER, DALTON EDWARD | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | — |
| 18690345 | METHODS OF BIOMOLECULE DISPLAY | OLSON, ALEXANDRA NADINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | — |
| 18690456 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | SWIFT, CANDICE LEE | — |
| 18690114 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | MCKOY, QUINCY ANDRE | — |
| 18037063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTESTINAL CANCER | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1657 | 1 |
| 1626 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710471 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | MOAZZAMI, NAGHMEH NINA | 1652 | §103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18690345 | METHODS OF BIOMOLECULE DISPLAY | OLSON, ALEXANDRA NADINE | — | §101§102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690456 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | SWIFT, CANDICE LEE | 1657 | §112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690114 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | MCKOY, QUINCY ANDRE | 1626 | §102 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18547085 | FUSION PROTEINS COMPRISING TWO RING DOMAINS | KIEFER, DALTON EDWARD | 1652 | §102§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18037063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTESTINAL CANCER | OUSPENSKI, ILIA I | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial